Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|December 8, 2024
Dr Zackon on the Use of Bispecific Antibodies in the Community Setting for R/R Myeloma
Author(s)Ira Zackon, MD
Listen
0:00 / 0:00
Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.
Advertisement
Ira Zackon, MD, hematologist, medical oncologist, New York Oncology Hematology; senior medical director, Ontada, discusses findings from a presentation at the
Advertisement
Related to this article
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
The OncFive: Top Oncology Articles for the Week of 7/12
5